Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
116 rows where has_activation_state_pdb_pair = 0, has_known_aptamer = 1 and surface_class = "A2_pm_peripheral" sorted by evidence_priority descending
This data as json, CSV (advanced)
Suggested facets: aptamer_count_pubmed
surface_class 1
- A2_pm_peripheral · 116 ✖
has_known_aptamer 1
- 1 · 116 ✖
has_activation_state_pdb_pair 1
- - · 116 ✖
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P15056 | BRAF | Serine/threonine-protein kinase B-raf | Tier 1 | 0.803 | 1 | A2_pm_peripheral | 100 | 66.38 | 0 | 0 | 1 | 6 | 39624124, 34874026, 33497198, 31726389, 24486214, 11856330 | 1 | cardiofaciocutaneous syndrome | 0.8764542776642054 | ||
| P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | Tier 1 | 0.799 | 1 | A2_pm_peripheral | 75 | 67.5 | 0 | 0 | 1 | 4 | 15112994, 12173045, 11856330, 9883908 | 1 | Noonan syndrome | 0.8625147809861142 | ||
| Q06187 | BTK | Tyrosine-protein kinase BTK | Tier 1 | 0.794 | 1 | A2_pm_peripheral | 100 | 84.44 | 0 | 0 | 1 | 1 | 41951939 | 1 | X-linked agammaglobulinemia | 0.8454716106068291 | ||
| O60315 | ZEB2 | Zinc finger E-box-binding homeobox 2 | Tier 1.5 | 0.789 | 1 | A2_pm_peripheral | 1 | 48.16 | 0 | 0 | 1 | 3 | 27719642, 24146916, 18698484 | 1 | Mowat-Wilson syndrome | 0.8313744323041312 | ||
| Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Tier 1 | 0.788 | 1 | A2_pm_peripheral | 94 | 83.25 | 0 | 0 | 1 | 1 | 29580944 | 1 | cardiofaciocutaneous syndrome | 0.825549979325162 | ||
| P11274 | BCR | Breakpoint cluster region protein | Tier 1.5 | 0.785 | 1 | A2_pm_peripheral | 5 | 64.81 | 0 | 0 | 1 | 20 | 41951939, 41535871, 40882628, 37937247, 37103734, 32929022, 32507237, 31825964, 31650445, 31295447, 29299123, 28686804, 25809097, 23836560, 22411871, 21810089, 21653319, 21030439, 16990253, 11713794 | 1 | chronic myelogenous leukemia | 0.8183048540102864 | ||
| P01111 | NRAS | GTPase NRas | Tier 1 | 0.783 | 1 | A2_pm_peripheral | 35 | 92.06 | 0 | 0 | 1 | 2 | 39952900, 39371477 | 1 | Noonan syndrome 6 | 0.8087775198380727 | ||
| O60674 | JAK2 | Tyrosine-protein kinase JAK2 | Tier 1 | 0.78 | 1 | A2_pm_peripheral | 100 | 86.88 | 0 | 0 | 1 | 8 | 41455398, 34121564, 32985358, 31279934, 30415442, 25809097, 22411871, 20711698 | 1 | polycythemia vera | 0.8000866241942614 | ||
| P01137 | TGFB1 | Transforming growth factor beta-1 proprotein | Tier 1 | 0.78 | 1 | A2_pm_peripheral | 20 | 79.56 | 1 | 0 | 1 | 4 | 38132522, 32370304, 16775010, 11856769 | 1 | Camurati-Engelmann disease | 0.7995305374459716 | ||
| P98170 | XIAP | E3 ubiquitin-protein ligase XIAP | Tier 1 | 0.78 | 1 | A2_pm_peripheral | 74 | 74.25 | 0 | 0 | 1 | 4 | 35383192, 29864441, 27514505, 26318819 | 1 | X-linked lymphoproliferative disease | 0.8013347966323413 | ||
| Q9UHD9 | UBQLN2 | Ubiquilin-2 | Tier 1 | 0.778 | 1 | A2_pm_peripheral | 4 | 61.03 | 0 | 0 | 1 | 2 | 23541532 | 1 | amyotrophic lateral sclerosis type 15 | 0.7942015735994536 | ||
| Q9ULC3 | RAB23 | Ras-related protein Rab-23 | Tier 1.5 | 0.776 | 1 | A2_pm_peripheral | 6 | 79.56 | 1 | 0 | 1 | 1 | 23618401 | 1 | RAB23-related Carpenter syndrome | 0.7879955689930709 | ||
| O15294 | OGT | UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit | Tier 1 | 0.77 | 1 | A2_pm_peripheral | 44 | 93.06 | 0 | 0 | 1 | 2 | 36868188, 36626902 | 1 | intellectual disability, X-linked 106 | 0.7660009745204424 | ||
| P55263 | ADK | Adenosine kinase | Tier 1.5 | 0.769 | 1 | A2_pm_peripheral | 4 | 93.31 | 0 | 0 | 1 | 2 | 26051465 | 1 | adenosine kinase deficiency | 0.7617058236708037 | ||
| Q92743 | HTRA1 | Serine protease HTRA1 | Tier 1 | 0.768 | 1 | A2_pm_peripheral | 18 | 83.25 | 1 | 0 | 1 | 1 | 31988066 | 1 | cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 | 0.7611877816680132 | ||
| P35221 | CTNNA1 | Catenin alpha-1 | Tier 1 | 0.765 | 1 | A2_pm_peripheral | 10 | 82.94 | 1 | 0 | 1 | 2 | 40265971 | 1 | Butterfly-shaped pigment dystrophy | 0.7487735496199569 | ||
| P26038 | MSN | Moesin | Tier 1 | 0.755 | 1 | A2_pm_peripheral | 10 | 86.38 | 0 | 0 | 1 | 65 | 41813080, 41784619, 41611946, 40904334, 40886652, 40258621, 40222299, 39454415, 39053429, 38856817, 38759442, 38687941, 38561432, 38446130, 38349197, 38295649, 38266273, 37869770, 37806507, 37423650, 37353120, 37062561, 37058944, 36982925, 36843953, 36700559, 36562728, 36179642, 35026109, 34893239, 34538325, 33960345, 33727809, 33528465, 33149582, 32882423, 32291531, 32170403, 31872318, 31792209, 31213813, 31072481, 30985076, 30865739, 32254866, 29955964, 29568450, 29136862, 28917759, 28832225 | 1 | combined immunodeficiency due to moesin deficiency | 0.7157135146765757 | ||
| P84077 | ARF1 | ADP-ribosylation factor 1 | Tier 1 | 0.755 | 1 | A2_pm_peripheral | 36 | 85.94 | 1 | 0 | 1 | 3 | 30965174, 11320245 | 1 | periventricular nodular heterotopia 8 | 0.7173626622431929 | ||
| Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Tier 1 | 0.753 | 1 | A2_pm_peripheral | 41 | 73.69 | 0 | 0 | 1 | 2 | 32636813, 20564698 | 1 | intellectual developmental disorder with macrocephaly, seizures, and speech delay | 0.7110292416229067 | ||
| P35241 | RDX | Radixin | Tier 1.5 | 0.749 | 1 | A2_pm_peripheral | 2 | 86.56 | 0 | 0 | 1 | 2 | 33253235, 30700648 | 1 | hearing loss, autosomal recessive | 0.6973070672344621 | ||
| Q13546 | RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | Tier 1 | 0.749 | 1 | A2_pm_peripheral | 39 | 69.75 | 1 | 0 | 1 | 2 | 41290466, 35919280 | 1 | immunodeficiency 57 | 0.698121745966467 | ||
| P50148 | GNAQ | Guanine nucleotide-binding protein G(q) subunit alpha | Tier 1 | 0.748 | 1 | A2_pm_peripheral | 30 | 93.0 | 1 | 0 | 1 | 1 | 40015005 | 1 | Sturge-Weber syndrome | 0.6941111530708174 | ||
| P61586 | RHOA | Transforming protein RhoA | Tier 1 | 0.744 | 1 | A2_pm_peripheral | 100 | 93.56 | 0 | 0 | 1 | 4 | 25645980, 19389625, 12927206, 12123800 | 1 | ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies | 0.6804889074382072 | ||
| Q00535 | CDK5 | Cyclin-dependent kinase 5 | Tier 1 | 0.744 | 1 | A2_pm_peripheral | 10 | 91.56 | 0 | 0 | 1 | 4 | 33291667, 33200349 | 1 | Alzheimer disease | 0.6800338890220147 | ||
| O95786 | RIGI | Antiviral innate immune response receptor RIG-I | Tier 1 | 0.735 | 1 | A2_pm_peripheral | 44 | 85.19 | 1 | 0 | 1 | 6 | 34487794, 33253193, 32946572, 31600868, 26018150, 22127865 | 1 | Singleton-Merten dysplasia | 0.6485708110478319 | ||
| P26196 | DDX6 | Probable ATP-dependent RNA helicase DDX6 | Tier 1 | 0.734 | 1 | A2_pm_peripheral | 9 | 84.06 | 0 | 0 | 1 | 2 | 34132569 | 1 | intellectual developmental disorder with impaired language and dysmorphic facies | 0.6482686715821397 | ||
| P61769 | B2M | Beta-2-microglobulin | Tier 1 | 0.725 | 1 | A2_pm_peripheral | 100 | 94.06 | 0 | 0 | 1 | 15 | 41850110, 40373155, 38904251, 40658810, 35026285, 32631049, 29281176, 28960840, 25100729, 20616783, 19137104, 17878167 | 1 | Immunodeficiency by defective expression of HLA class 1 | 0.6180318849819645 | ||
| P23921 | RRM1 | Ribonucleoside-diphosphate reductase large subunit | Tier 1 | 0.724 | 1 | A2_pm_peripheral | 12 | 92.25 | 1 | 0 | 1 | 1 | 21955496 | 1 | non-small cell lung carcinoma | 0.6122881671315019 | ||
| P43405 | SYK | Tyrosine-protein kinase SYK | Tier 1 | 0.723 | 1 | A2_pm_peripheral | 93 | 84.0 | 0 | 0 | 1 | 2 | 35782912, 31825964 | 1 | immunodeficiency 82 with systemic inflammation | 0.608506293550361 | ||
| P06241 | FYN | Tyrosine-protein kinase Fyn | Tier 1 | 0.721 | 1 | A2_pm_peripheral | 53 | 80.81 | 0 | 0 | 1 | 5 | 38559166, 37149826, 34757788, 32668060, 29754498 | 1 | chronic myelogenous leukemia | 0.6018224074412558 | ||
| P32121 | ARRB2 | Beta-arrestin-2 | Tier 1.5 | 0.719 | 1 | A2_pm_peripheral | 1 | 83.81 | 1 | 0 | 1 | 4 | 24736311, 40652239, 29054528 | 1 | cancer | 0.5962458729823639 | ||
| P07947 | YES1 | Tyrosine-protein kinase Yes | Tier 1 | 0.716 | 1 | A2_pm_peripheral | 1 | 81.88 | 0 | 0 | 1 | 1 | 34757788 | 1 | chronic myelogenous leukemia | 0.5851678597856559 | ||
| P09769 | FGR | Tyrosine-protein kinase Fgr | Tier 1.5 | 0.716 | 1 | A2_pm_peripheral | 3 | 82.19 | 0 | 0 | 1 | 1 | 39564692 | 1 | chronic myelogenous leukemia | 0.5869168331059803 | ||
| P45984 | MAPK9 | Mitogen-activated protein kinase 9 | Tier 1 | 0.707 | 1 | A2_pm_peripheral | 5 | 81.44 | 0 | 0 | 1 | 1 | 41505229 | 1 | cancer | 0.5569349147269519 | ||
| P04406 | GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | Tier 1 | 0.706 | 1 | A2_pm_peripheral | 21 | 98.12 | 1 | 0 | 1 | 11 | 39832592, 39429683, 35821507, 28131717, 26310631, 23215008, 37500700, 16115199 | 1 | neurodegenerative disease | 0.55307368855439 | ||
| P42680 | TEC | Tyrosine-protein kinase Tec | Tier 1.5 | 0.705 | 1 | A2_pm_peripheral | 1 | 85.0 | 0 | 0 | 1 | 13 | 39352470, 39329798, 36414190, 36105684, 35624657, 35462326, 35006795, 30578658, 30398689, 27548775, 26843427, 25016253, 24875764 | 1 | alopecia areata | 0.5491699656070116 | ||
| O75534 | CSDE1 | Cold shock domain-containing protein E1 | Tier 1 | 0.704 | 1 | A2_pm_peripheral | 5 | 79.56 | 0 | 0 | 1 | 1 | 10101203 | 1 | neurodegenerative disease | 0.5472997885061864 | ||
| P17252 | PRKCA | Protein kinase C alpha type | Tier 1.5 | 0.704 | 1 | A2_pm_peripheral | 6 | 86.38 | 0 | 0 | 1 | 1 | 41505229 | 1 | acute myeloid leukemia | 0.547429504944985 | ||
| P67809 | YBX1 | Y-box-binding protein 1 | Tier 1 | 0.703 | 1 | A2_pm_peripheral | 11 | 61.84 | 0 | 0 | 1 | 9 | 31989173, 31160337, 22730292, 21245151, 16093451 | 1 | dengue disease | 0.5435698373845997 | ||
| P34947 | GRK5 | G protein-coupled receptor kinase 5 | Tier 1 | 0.702 | 1 | A2_pm_peripheral | 23 | 90.38 | 0 | 0 | 1 | 1 | 18230760 | 1 | venous thromboembolism | 0.5394311062516939 | ||
| Q92888 | ARHGEF1 | Rho guanine nucleotide exchange factor 1 | Tier 1 | 0.695 | 1 | A2_pm_peripheral | 7 | 73.19 | 0 | 0 | 1 | 6 | 25645980, 23757206, 25033804, 22689339, 19389625, 12123800 | 1 | immunodeficiency 62 | 0.5170912094162261 | ||
| Q96PY5 | FMNL2 | Formin-like protein 2 | Tier 1.5 | 0.695 | 1 | A2_pm_peripheral | 1 | 76.44 | 0 | 0 | 1 | 1 | 41149482 | 1 | open-angle glaucoma | 0.5157968177633478 | ||
| P09543 | CNP | 2',3'-cyclic-nucleotide 3'-phosphodiesterase | Tier 1.5 | 0.689 | 1 | A2_pm_peripheral | 1 | 87.25 | 0 | 0 | 1 | 9 | 40034273, 38569854, 37704353, 35528922, 31171207, 30089209, 27192549, 19021295 | 1 | myopia 2, autosomal dominant | 0.49606855995054094 | ||
| P31948 | STIP1 | Stress-induced-phosphoprotein 1 | Tier 1.5 | 0.689 | 1 | A2_pm_peripheral | 8 | 89.75 | 1 | 0 | 1 | 7 | 41406518, 38012811, 34831332, 32614006, 27681499, 24654750, 24013070 | 1 | neurodegenerative disease | 0.4967711525222825 | ||
| P21980 | TGM2 | Protein-glutamine gamma-glutamyltransferase 2 | Tier 1.5 | 0.688 | 1 | A2_pm_peripheral | 17 | 92.88 | 1 | 0 | 1 | 1 | 35980938 | 1 | neurodegenerative disease | 0.49455272812698803 | ||
| P49327 | FASN | Fatty acid synthase | Tier 1 | 0.68 | 1 | A2_pm_peripheral | 34 | 85.44 | 1 | 0 | 1 | 1 | 41854184 | 1 | dengue disease | 0.46815584653391107 | ||
| Q07812 | BAX | Apoptosis regulator BAX | Tier 1 | 0.679 | 1 | A2_pm_peripheral | 37 | 85.94 | 0 | 0 | 1 | 21 | 41323565, 41237573, 40761795, 40148451, 39946362, 39318128, 37301952, 36907299, 36843953, 36309655, 32987067, 32486412, 31747745, 30005287, 27843907, 26325285, 24481451, 23582862, 23528042, 21563784, 21362508 | 1 | T-cell acute lymphoblastic leukemia | 0.4626258720529755 | ||
| P09104 | ENO2 | Gamma-enolase | Tier 1 | 0.676 | 1 | A2_pm_peripheral | 16 | 97.06 | 0 | 0 | 1 | 1 | 36384120 | 1 | neurodegenerative disease | 0.4533558777394424 | ||
| P07355 | ANXA2 | Annexin A2 | Tier 1 | 0.673 | 1 | A2_pm_peripheral | 41 | 94.25 | 0 | 0 | 1 | 12 | 40685636, 31029658, 29906496, 24489826, 35211356, 29982617, 27890659, 27777972, 26061649 | 1 | neurodegenerative disease | 0.4424399692174707 | ||
| P63098 | PPP3R1 | Calcineurin subunit B type 1 | Tier 1.5 | 0.673 | 1 | A2_pm_peripheral | 21 | 91.12 | 1 | 0 | 1 | 2 | 39263947 | 1 | Abnormality of the skeletal system | 0.44389060142742937 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;